头孢米诺和头孢美唑对产与不产超广谱β-内酰胺酶肠杆菌科体外抗菌活性的研究  

作　　者：徐晓平[1] 许健波[1] 胡俊青[1] 

机构地区：[1]浙江省金华市中心医院检验科,321000

出　　处：《浙江临床医学》2017年第8期1517-1518,共2页Zhejiang Clinical Medical Journal

摘　　要：目的 评价头孢米诺和头孢美唑对肠杆菌科大肠埃希菌和肺炎克雷伯杆菌的体外抗菌活性.方法 收集2014年1月至2015年12月临床科室分离出非重复的大肠埃希菌和肺炎克雷伯杆菌500例,采用琼脂稀释法测定头孢米诺和头孢咪唑的最低抑菌浓度（MIC）,将数据输入WHONET5.4进行耐药性分析.结果 500株大肠埃希菌和肺炎克雷伯杆菌中不产酶菌株179株（35.8%）,单产ESBLS株277株（55.4%）,单产AmpC株12株（2.4%）,产ESBLS＋AmpC株32株（6.4%）,头孢米诺和头孢美唑对不产酶和单产ESBLS的大肠埃希菌和肺炎克雷波菌具有良好的抗菌活性;头孢米诺和头孢美唑对产AmpC酶的大肠埃希菌和肺炎克雷伯菌抗菌活性差.结论 头孢米诺和头孢美唑对不产酶和单产ESBLS的大肠埃希菌和肺炎克雷伯杆菌具有良好的抗菌活性,提示头孢米诺和头孢美唑可用于上述敏感菌的治疗.Objective To evaluate the antimicrobial activity in vitro of cefmetazole and cefminox against Enterobacteriaceae strains such as Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamase（ESBLS）producing and non-producing. Methods A total of 500 E.coli and K.pneumoniae were isolated from January 2014 to December 2015. The levels of minimal inhibitory concentration of the agents were determined by agar dilution method. WHONET5.4 were used to analyse the data. Results Of the 500 E.coli and K. Pneumoniae strains ,156（31.2%） produced neither ESBLS nor AmpC,275（55%）produced ESBLS,11（2.2%）produced AmpC,58（11.6%）produced both ESBLS and AmpC. Cefminox showed excellent antibacterial against both ESBLS-negative and ESBLS-positive E.coli and K. Pneumoniae strains. Cefminox demonstrated better antimicrobial activity than that of cefmetazole.The activity of cefminox was poor against AmpC-proceding E.coli and K. Pneumoniae. Conclusion Cefminox has a broad-spectrum antimicrobial activity against both ESBLS-negative and ESBLS-positive E.coli and K. Pneumoniae. These results indicate that cefminox is suitable for the treatment of infection caused by such cefminox-sensitive isolates.

关 键 词：头孢米诺 头孢美唑 头霉素类 超广谱Β-内酰胺酶 抗菌活性 

分 类 号：R978.1[医药卫生—药品]